Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719656PMC

Publication Analysis

Top Keywords

[reactivation cryopyrin-associated
4
cryopyrin-associated periodic
4
periodic syndrome
4
syndrome vaccination
4
vaccination patient
4
patient candidate
4
candidate immunosuppression]
4
[reactivation
1
periodic
1
syndrome
1

Similar Publications

Anakinra Therapy for Non-cancer Inflammatory Diseases.

Front Pharmacol

November 2018

Department of Medicine, Radboud University Medical Center, Nijmegen, Netherlands.

Interleukin-1 (IL-1) is the prototypical inflammatory cytokine: two distinct ligands (IL-1α and IL-1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory mediators, including prostaglandins, cytokines, and chemokines. IL-1α is constitutively present in endothelial and epithelial cells, whereas IL-1β is inducible in myeloid cells and released following cleavage by caspase-1. Over the past 30 years, IL-1-mediated inflammation has been established in a broad spectrum of diseases, ranging from rare autoinflammatory diseases to common conditions such as gout and rheumatoid arthritis (RA), type 2 diabetes, atherosclerosis, and acute myocardial infarction.

View Article and Find Full Text PDF

Objectives: Pneumococcal, tetanus and influenza vaccinations are recommended for patients with cryopyrin-associated periodic syndromes (CAPS) when treated with immunosuppressive medication. The aim of this publication is to report the safety of pneumococcal and other vaccinations in CAPS patients.

Methods: All CAPS patients followed in the β-CONFIDENT (Clinical Outcomes and Safety Registry study of Ilaris patients) registry were analysed if they had received a vaccination.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!